Suxibuzone and Suxibuzone sachet

Meets the RLD Heptral and Ready for tech transfer, Dossier readiness Q2 2027

Deferasirox Sprinkle granules were developed to improve palatability and patient adherence.
and it is in compliance to EU RLD Jadenu
Dossier Ready for ROW and emerging markets
Dossier Ready for EU- Q2 2027

The API will be used for the development of generic version of Desferal injection 

Ertugliflozin tablets, marketed under the brand names STEGLATRO, STEGLUJAN, and SEGLUROMET, is still under development.

Rare disease product
Developed in India, a generic version of Endari approved in US

Dossier ready for emerging Markets
Will undergo clinical Trials for sickle cell in Q3 2026

Meets the Japan RLD Kremezin granules, worldwide charcoal tablets are already available. The carbon in granule form is more easy to use
Dossier Readiness Q4 2026

RLD is Renvela (Genzyme). It is open for outlicensing for EU, Canada, Australia and Emerging countries. 

RLD is Renvela (Genzyme). It is open for outlicensing for EU, Canada, Australia and Emerging countries. 

RLD: Subvenite US
Tech Transfer Readiness- Q3 2027
Dossier Readiness Q2 2028

RLD: Rezdiffra
Tech Transfer readiness- Q4 2027

RLD: Evrsdi,
API -under development
FDF- Tech Transfer Readiness- Q3 2027
Dossier Readiness- Q3 2028

Meets the RLD EU, US InvoKana, Ready for tech transfer, Dossier readiness Q2 2027

Rajah Dubey, Chief Technical Strategist of SRS Life Sciences, speaks with CPHI TV at CPHI Worldwide in Madrid.